التفاصيل البيبلوغرافية
| العنوان: |
Semaglutide and kidney function: friends or enemies? |
| المؤلفون: |
Giofrè, Federica, Trapanese, Vincenzo, Natale, Maria Resilde, Vatalaro, Clara, Cosentino, Francesca, Melina, Melania, Pelle, Maria Chiara, Carullo, Nazareno, Capria, Maria, Arturi, Franco |
| المصدر: |
Italian Journal of Medicine; 2024, Vol. 18, p1-3, 3p |
| مستخلص: |
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RAs) approved for the treatment of type 2 diabetes mellitus (T2DM) and chronic weight management in obesity. GLP-1RAs are being investigated to slow the decline of kidney function in type 2 diabetics with chronic kidney disease. These agents prevent renal complications and have proven beneficial effects on cardiac outcomes. We describe a rare case of semaglutide-induced acute kidney injury (AKI) in a young woman with obesity, T2DM, hypertensive cardiomyopathy, and no pre-existing chronic kidney disease (CKD). This case is relevant as GLP1-RAs is used frequently in patients with and without kidney disease. Currently, only 3 cases of AKI ascribed to semaglutide of which only 1 without CKD have been described. Only in this case, kidney function improves after semaglutide discontinuation. However, because GLP1-RAs will be prescribed more and more frequently, we sought to highlight this possible, serious adverse effect of semaglutide. [ABSTRACT FROM AUTHOR] |
|
Copyright of Italian Journal of Medicine is the property of PAGEPress and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
Full Text Finder